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Abstract
Background: Medical implants often fail as a result of so-called foreign body reactions during
which inflammatory cells are recruited to implant surfaces. Despite the clinical importance of this
phenomenon, the mechanisms involved in these reactions to biomedical implants in humans are not
well understood. The results from animal studies suggest that both fibrinogen adsorption to the
implant surface and histamine release by local mast cells are involved in biomaterial-mediated acute
inflammatory responses. The purpose of this study was to test this hypothesis in humans.
Methods:  Thirteen male medical student volunteers (Caucasian, 21–30 years of age) were
employed for this study. To assess the importance of fibrinogen adsorption, six volunteers were
implanted with polyethylene teraphthalate disks pre-coated with their own (fibrinogen-containing)
plasma or (fibrinogen-free) serum. To evaluate the importance of histamine, seven volunteers were
implanted with uncoated disks with or without prior oral administration of histamine receptor
antagonists. The acute inflammatory response was estimated 24 hours later by measuring the
activities of implant-associated phagocyte-specific enzymes.
Results: Plasma coated implants accumulated significantly more phagocytes than did serum coated
implants and the recruited cells were predominantly macrophage/monocytes. Administration of
both H1 and H2 histamine receptor antagonists greatly reduced the recruitment of macrophages/
monocytes and neutrophils on implant surfaces.
Conclusion: In humans – as in rodents – biomaterial-mediated inflammatory responses involve at
least two crucial events: histamine-mediated phagocyte recruitment and phagocyte accumulation
on implant surfaces engendered by spontaneously adsorbed host fibrinogen. Based on these results,
we conclude that reducing fibrinogen:surface interactions should enhance biocompatibility and that
administration of histamine receptor antagonists prior to, and shortly after, medical device
implantation should improve the functionality and longevity of medical implants.
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Background
Implanted devices are increasingly important in the prac-
tice of medicine. In an NIH news release dated January 5th
2000, it was estimated that 8 to 10 percent of the U. S.
population currently have permanent medical implants
[1]. Although most implant materials are inert, non-
immunogenic and non-toxic, devices made of such mate-
rials often trigger a variety of adverse reactions. These
include surface-mediated thrombosis associated with
blood contact surfaces [2], complement activation
induced by haemodialysis membranes [3], inflammation
surrounding many types of implants [4], device-centered
infections [5] and fibrotic tissue formation around tissue
implants and prostheses [6]. These complications may
cause the failure of many types of medical implants, often
requiring surgical removal and replacement, increasing
both the risk to patients and the cost of health care. Con-
sequently, intensive research efforts have been devoted to
the development of novel strategies to improve tissue
compatibility of medical devices. However, improve-
ments in biocompatibility have been hindered by our lack
of understanding of the basic mechanisms involved in
human tissue responses to biomaterial implants.
Because biomaterials spontaneously accumulate a layer of
adsorbed plasma proteins prior to inflammatory cell accu-
mulation, it is widely accepted that the types and species
of adsorbed proteins play an important role in the patho-
genesis of biomaterial-mediated acute inflammatory
responses. Using an animal implantation model, we ear-
lier found that spontaneously adsorbed (and partially
denatured) fibrinogen is a critical mediator of acute
inflammatory responses to biomaterial implants [7]. In
support of this, we observed much less phagocyte accu-
mulation on the surfaces of serum-coated implants than
on implants coated with plasma. As a more direct test,
hypo-fibrinogenemic mice were generated with repeated
ancrod injection. Biomaterial implants in these mice
failed to accumulate adherent phagocytes (unless the
implants were pre-coated with murine fibrinogen) [7]. We
subsequently found that, following initial adsorption on
hydrophobic biomaterial surfaces, fibrinogen undergoes
conformational changes which expose previously occult
epitopes on the gamma chain of fibrinogen ('P1' (γ190–
202) and 'P2' (γ377–392)) [8,9]. These newly exposed
epitopes are responsible for triggering the recruitment and
activation of phagocytes, early events in the cascade of
events involved in foreign body reactions.
In mice, the initial recruitment of inflammatory cells to
experimental implants is mediated by histamine. Mast
cell deficient mice showed greatly diminished phagocyte
accumulation on implants and administration of H1 and
H2 receptor antagonists to normal mice substantially
reduced phagocyte recruitment [10].
Despite these earlier observations, it has remained uncer-
tain whether adsorbed fibrinogen and histamine release
play similar roles in triggering foreign body reactions in
humans. The goal of this investigation was to determine
whether these earlier results in animal models were
directly pertinent to humans given experimental biomate-
rial implants.
Methods
Test materials and chemicals
Polyethylene terephthalate (PET) film, type A, 0.005 mm
thick, was obtained from Cadillac Plastic and Chemical
(Birmingham, MI, USA). All other reagents were pur-
chased from Sigma Chemical Co. (St Louis, MO, USA).
Preparation of uncoated and protein-coated PET disks
The PET film was cut into circular disks of 12 mm diame-
ter with punch and die set (Precision, Downers Grove, IL).
The punch and die set was sharpened prior to cutting to
ensure smooth edge. The disks were first cleaned with
multiple changes of 100% ethanol to remove the residual
fibers and debris. The disks were then washed with several
changes of 70% ethanol and then autoclaved at 125°C for
15 minutes. To test the importance of surface fibrinogen
in the aetiology of biomaterial-mediated inflammatory
responses, 20 ml of venous blood from each volunteer
was drawn into collection tubes with and without antico-
agulant (sodium heparin). The heparinized blood tubes
were centrifuged at 200 × g for 10 minutes to produce
plasma. Clot tubes without anticoagulant were cooled to
4°C for 120 min to allow for blood coagulation and then
centrifuged to produce sera. The PET disks were incubated
in plasma or serum from each volunteer overnight (12 h)
under sterile conditions in sealed vials in an incubator at
37°C. The protein-coated disks were thoroughly washed
in sterile phosphate buffered saline (PBS) before implan-
tation.
Human volunteers
We recruited 13 healthy male Caucasian medical student
volunteers aged 21–30 years. They were divided into two
groups where 6 (average age = 24.5 years) took part in
experiments on the effects of histamine receptor antago-
nists and 7 (average age = 23.8 years) were involved in
studies of the effects of fibrinogen. None of the volunteers
had taken any medication for two weeks prior to the
experiments. These studies were approved by the Human
Ethics Committee of the Linköping University Hospital.
Following written and oral instruction, all volunteers gave
written consent to their participation.Journal of Translational Medicine 2007, 5:31 http://www.translational-medicine.com/content/5/1/31
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Experimental setup
Effects of fibrinogen (n = 7)
Day 1: Withdrawal of blood to obtain plasma and sera.
PET disks were incubated with plasma and sera for 12
hours.
Day 2: Implantation of an autologous plasma coated disk
in the left arm and an autologous serum coated disk in the
right arm of all 7 volunteers.
Day 3: Explantation of both disks after 24 hours.
Antihistamine treatment (n = 6)
Day 1: Implantation of an uncoated disk in the right arm.
Day 2: Explantation of the disk after 24 hours. The same
patients were immediately given 10 mg of the H1 hista-
mine receptor antagonist Cetirizine and 20 mg of the H2
histamine receptor antagonist Famotidine, both per os.
Two hours later, a new uncoated disk was implanted in
the left arm. The administration of Famotidine was
repeated 12 hours after the first dose to ensure an ade-
quate plasma level of the drug and continuous histamine
receptor blockade.
Day 3: Explantation of the second disk after 24 hours
implantation.
Surgical procedure for biomaterial implantation
After sterile preparation and disinfection of the skin on
the inside of the upper arm with 0.02% chlorhexidine and
70% ethanol, local anaesthesia was performed using 1 ml
lidocaine (10 mg/ml). A transverse 15 mm long incision
was made 5 min after injection of the anaesthetic and a
small subcutaneous pocket formed. A sterile PET disk,
either coated or uncoated, was then placed in the pocket
and the skin was closed using sterile tape (Steristrips®, 3
M). Explantation was performed 24 h after implantation
as follows: the wound-tape was removed, the wound
edges separated and the disks removed with a forceps for
later analyses. The skin was then closed with sterile tape.
The 24 hour time period was chosen because our earlier
investigations in mice indicated that in a subcutaneous
implantation model this was the time of maximal accu-
mulation of PMN and MØ. A pilot study was also carried
out in 2 human volunteers (in addition to the 13 human
volunteers mentioned above). The results from this lim-
ited preliminary human trial indicated that 24 hour-
implantation is appropriate to assess acute inflammatory
responses to biomaterial implants in humans. However,
we should note that it is not presently known whether this
represents the time of maximal phagocyte accumulation.
Throughout the study, no voluteer had prominent signs of
inflammatory reactions and erythema in or around the
implantation sites. Because of the localized and minimal
inflammatory responses, it is unlikely that the tissue
responses to the first implants would affect responses to
the second implants in the same volunteers.
Analyses of biomaterial-mediated inflammatory responses
Immediately following explantation, the PET disks were
washed with isotonic PBS. To reduce the edge effect on the
quantification of implant-associated inflammatory
responses, the edges of all explanted disks were cleaned by
sliding the edges of the disks across tissue paper to dis-
lodge cells adherent to the implant edge. The disks were
then placed in 0.6 ml of 1% (vol/vol) Triton X-100 for 1
hour to release cytoplasmic and granular enzymes from
implant-associated cells [7-10]. Because biomaterial-
mediated inflammatory responses are reflected by the
accumulation of phagocytes on implant surfaces, the
number of adherent phagocytes was taken as a measure of
the extent of foreign body reactions. Implant-associated
myeloperoxidase (MPO) and non-specific esterase (NSE)
were quantified to assess the numbers of adherent poly-
morphonuclear neutrophils [PMN] and macrophages/
monocytes [MØ], respectively.
MPO was measured by the guaiacol reaction [7-10] in the
presence of 1 mM (final concentration) 3-amino-1,2,4-tri-
azole to inhibit eosinophil peroxidase [11]. Total MPO
activity was taken as a measure of surface associated PMN.
Control studies on purified PMN from human venous
blood indicated that the MPO activity of human periph-
eral PMN is about 45 nU/cell.
Non-specific esterase (NSE), a cytoplasmic enzyme,
resides specifically in monocytes/macrophages [12] and
was used to assess the numbers of adherent MØ [7-10].
NSE activity was determined by measuring the rate of
hydrolysis of p-nitrophenyl butyrate [13] in the presence
of a cholinesterase inhibitor, eserine (10 mM, final con-
centration) [14]. Control studies on human peritoneal
macrophages (recovered from peritoneal lavage fluids
from patients being given chronic ambulatory peritoneal
dialysis) indicated that the NSE activities of human MØ
are about 20 nU/cell.
Statistical and power analyses
As the results were normally distributed, paired Student's
t-test was used. A p-value of <0.05 was considered signifi-
cant. The power analyses of the number of test subjects
were carried out using G* power 3 program [15].
Results
Importance of fibrinogen adsorption in implant-mediated 
acute inflammatory response in humans
To determine the importance of implant-bound fibrino-
gen in triggering biomaterial-mediated inflammatoryJournal of Translational Medicine 2007, 5:31 http://www.translational-medicine.com/content/5/1/31
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responses in humans, PET disks precoated with the
plasma or serum of each volunteer were implanted subcu-
taneously and then retrieved 24 hours later. As was true in
the mouse model, plasma-coated surfaces accumulated
many more PMN and MØ compared to serum-coated
disks. The average numbers of adherent PMN and MØ on
plasma-coated surfaces were 4–5 fold higher than those
on serum-coated disks (Figure 1.A). Interestingly, and in
contrast to mice, the majority (>95%) of implant-associ-
ated phagocytes were MØ (possibly a function of differ-
ences in the site of implantation – intraperitoneal in mice
and subcutaneous in humans). Perhaps most impor-
tantly, the aggregate numbers of adherent phagocytes
(PMN+MØ) on plasma coated surfaces were significantly
higher than those on serum coated surfaces (Figure 1.B).
Power analyses were carried out using G* power 3 and the
results indicated that 7 volunteers recruited for this inves-
tigation were sufficient to achieve power = 0.8 and alpha
= 0.05 in all comparisons (i.e., PMN, MØ and PMN + MØ
numbers).
Importance of histamine in implant-mediated 
inflammatory responses in mice and humans
In previous work with the mouse implantation model, we
found that histamine receptor antagonists could be used
to reduce biomaterial-mediated acute inflammatory
responses [Error! Bookmark not defined.] and that the
simultaneous administration of H1 and H2 histamine
receptor antagonists greatly decreased the numbers of
implant-associated PMN and MØ. As was true in mice,
administration of a combination of H1 and H2 histamine
receptor antagonists suppressed the accumulation of both
PMN and MØ on subcutaneous implants in humans (Fig-
ure 2). The accumulation of PMN (p = 0.016), MØ (p =
0.011), and aggregate numbers of PMN + MØ (p = 0.011)
was significantly less on uncoated PET disks implanted in
volunteers treated with the histamine receptor antagonists
compared with implants in the same volunteers without
antihistamine treatment. G* 3 power analyses were also
carried out in this case and revealed that 6 patients were
sufficient to achieve power >0.8 and alpha = 0.05.
Discussion
The implantation of medical devices often leads to foreign
body reactions which are driven by the accumulation and
activation of inflammatory cells. These acute inflamma-
tory responses are very often followed by chronic inflam-
mation and fibrosis [16]. These reactions have been
linked to the degradation and failure of many types of
implants, including pacemaker leads [17], mammary
prostheses [18], temporomandibular [19] and other joint
implants [20]. To improve the biocompatibility and safety
of medical devices, intensive research efforts have been
placed on the development of biomaterials with
Phagocyte accumulation on the surfaces of PET disks implanted in human volunteers, precoated with either plasma or serum  derived from each volunteer Figure 1
Phagocyte accumulation on the surfaces of PET disks implanted in human volunteers, precoated with either plasma or serum 
derived from each volunteer. (A) Myeloperoxidase and non-specific esterase activities were measured on disks explanted after 
24 h to reflect the degree of accumulation of PMN and MØ, respectively. (B) The estimated numbers of adherent PMN, MØ, 
and total phagocytes (PMN+ MØ) were calculated. Vertical lines denote ± 1 Standard Deviation. Significance vs. plasma-coated 
disks: * p < 0.05.
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enhanced tissue compatibility. However, such efforts have
been hindered by the lack of knowledge of the mecha-
nisms governing foreign body reactions.
In an attempt to understand these basic mechanisms, we
earlier carried out a series of experiments using a murine
implantation model [4,7-10]. Our investigations revealed
that, rapidly following implantation, biomaterial surfaces
become covered with a layer of host proteins. We found
that the adsorption and later "denaturation" of fibrinogen
is the main factor in triggering biomaterial-mediated
inflammatory responses in mice [7]. Furthermore, it
appeared that histamine release by mast cells in the vicin-
ity of the implant was important in facilitating the recruit-
ment of inflammatory cells inasmuch as both mast cell
deficient mice and mice treated with histamine receptor
antagonists had greatly reduced acute inflammatory
responses to implanted biomaterials.
However, it was not clear whether these processes, found
to be important in mice, might be similarly crucial in
humans with implanted biomaterials. As a first test of this,
we have examined the importance of adsorbed fibrinogen
in prompting foreign body reactions in human volun-
teers. As was true in the earlier murine model, plasma
coated implants attracted significantly more phagocytes
than did serum coated implants in humans. The process
of inflammatory cell recruitment – in both mice and
humans – likely involves the tendency of fibrinogen to
adsorb and subsequently denature on the hydrophobic
surfaces of biomedical polymers [7]. The "denaturation"
of adsorbed fibrinogen is particularly important inas-
much as it leads to the exposure of two epitopes on the
fibrinogen gamma chain (P1 and P2) which are normally
occult in soluble fibrinogen. The exposure of these short
sequences is required for both the adhesion and activa-
tion of phagocytes [8,9]. Indeed, the degree of P1/P2
exposure engendered by different types of biomedical pol-
ymers predicts the extent of biomaterial-mediated inflam-
matory responses [9]. Furthermore, it appears that the
interaction between phagocytes and surface P1/P2
epitope is via the Mac-1 (CD11b/CD18) integrin, which is
upregulated on inflammatory cells recruited to the site of
the implant [21,22].
Our earlier animal studies also indicated that histamine,
released from activated mast cells, is critical to the recruit-
ment of phagocytes to both subcutaneous and intraperito-
neal implants [10]. This is in accord with numerous
observations that biomedical implants trigger both ede-
matous and hyperemic responses typically mediated by
histamine. The pro-inflammatory effects of the released
histamine evidently involve both H1 and H2 receptors
[10]. In the present experiments on humans, we observed
that treatment with a combination of H1 and H2 receptor
antagonists reduced by more than 80% the accumulation
of phagocytes on implant surfaces as was also true in the
murine models. Since histamine exerts its action on capil-
lary permeability and phagocyte transmigration through
endothelial barrier [23,24], it is likely that histamine
receptor antagonists diminish initial phagocyte recruit-
ment probably through suppression of implant-mediated
hyperemia and loosening of the endothelial barrier. This
suggests that histamine antagonist administration shortly
before and after the placement of biomedical implants in
humans may lessen the phagocyte-mediated foreign body
responses and later reactions such as fibrotic capsule for-
mation around implanted medical devices.
Conclusion
To the best of our knowledge, this is the first experimental
study on the molecular determinants of biomaterial-
mediated acute inflammatory responses in humans. The
results support the general conclusion that biocompatibil-
ity might be improved by the design of surfaces which
reduce fibrinogen adsorption and denaturation. The incu-
bation of medical devices with patient's serum may also
reduce foreign body reactions to the implants. Further-
more, our results confirm the importance of histaminic
responses in the pathogenesis of biomaterial-mediated
inflammatory responses. These latter observations may
have practical implications, in that treatment of implant
Phagocyte accumulation on the surfaces of PET disks  implanted in volunteers with and without the treatment of  H1 and H2 histamine receptor antagonists Figure 2
Phagocyte accumulation on the surfaces of PET disks 
implanted in volunteers with and without the treatment of 
H1 and H2 histamine receptor antagonists. (A) Myeloperoxi-
dase and non-specific esterase activities were measured to 
reflect the degree of accumulation of PMN and MØ, respec-
tively. (B) The estimated numbers of adherent PMN, MØ, 
and total phagocytes (PMN+ MØ) are calculated. Vertical 
lines denote ± 1 Standard Deviation. Significance vs. control 
volunteers (without antagonists): * p < 0.05.
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recipients with histamine receptor antagonists could be
used to limit both acute inflammatory responses and later
fibrotic reactions (which may directly stem from the acute
responses). Patients who might benefit from such antihis-
tamine treatment include those being treated with joint
implants, breast implants, tissue engineering implants
and drug delivery devices.
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